Skip to main content

Windward Bio Group AG

corporate_fare Company Profile

Windward Bio Group AG

WWB·NASDAQ·Life Sciences·CIK 0002145089

Windward Bio is a clinical-stage Swiss biotechnology company focused on developing ultra-long-acting antibody medicines for serious immunological diseases, with a primary emphasis on respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD), as well as dermatological indications like atopic dermatitis. The company's strategic approach centers on creating treatments that offer extended dosing intervals, aiming to address unmet needs in patient populations who struggle with frequent dosing regimens. Windward Bio's pipeline includes two clinical candidates. Its lead asset, WIN378, is an ultra-long-acting anti-TSLP (thymic stromal lymphopoietin) monoclonal antibody currently in Phase 2/3 trials for severe uncontrolled asthma and Phase 2 studies for COPD. WIN378 is designed for improved potency, extended half-life, and silenced effector function, and uniquely blocks TSLP signaling by binding to two different sites. The company also has WIN027, a clinical-stage, ultra-long-acting bispecific antibody targeting both TSLP and IL-13, which is expected to enter its first clinical studies in respiratory and dermatology by Q4 2026. Windward Bio was launched in January 2025 and is headquartered in Basel, Switzerland. Sources: [1] https://www.thepharmaletter.com/ones-to-watch/windward-bio [2] https://windwardbio.com/ [3] https://pitchbook.com/profiles/company/731954-08 [4] https://www.discoveripo.com/ipo/windward-bio-group [5] https://www.iposcoop.com/the-ipo-buzz-windward-bio-wwb-proposed-sets-terms-for-175-million-ipo/ [6] https://tickerspark.ai/market/windward-bio-ipo [7] https://www.ipox.com/ipo-calendar/windward-bio

Windward Bio Group AG (NASDAQ:WWB) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 5 items for WWB at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-18, rated 8/10. Across its 5 most recent items scored 7 or higher, the top rating is 8/10, with 2 rated 8 or above. Recent SEC coverage for WWB spans 4, 6-K.

Recent high-impact activity:

  • OrbiMed Buys $20M of Windward Bio IPO Shares at $17.00
  • Director Stampacchia Buys $29.75M of Windward Bio IPO Shares at $17.00
  • Windward Bio Closes $251.2M IPO and Sanofi Placement at $17.00
  • Windward Bio Closes IPO and Placement With $251.2M, Sanofi In for $50M
  • Windward Bio Raises $175M in IPO Priced at $17 a Share

Short Interest & Short Volume

On November 19, 2026, 57.5% of WWB volume reported to FINRA trade-reporting facilities was marked short.

Daily short volume (FINRA facilities)57.5% of 63,358 shares on November 19, 2026
5-day average short volume60.1%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for WWB, detected from its recent SEC filings · based on capital-structure filings through 2026-11-16.

IPO and Sanofi Placement Close · Dilution From New Shares

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Insider Transactions

WWB files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.

Browse all tickers starting with W →
$23.25 -3.17% today
52-week range · as of 2026-11-18 $18.35 – $33.98
Market cap
$1.38B
Volume
135.9K (0.2× avg)
3-mo avg 571.2K
Live data · 2026-11-20 20:37 UTC · Market open

show_chartPrice Chart

Loading chart...

feed WWB - Latest Insights

WWB
Nov 18, 2026, 5:08 PM EST
Filing Type: 4
Importance Score:
8
Price at Filing: $22.42
Real-time Price: $23.25 info
Change: +$0.830 (+4%) info
Market Cap: $1.384B info
WWB
Nov 18, 2026, 4:30 PM EST
Filing Type: 4
Importance Score:
8
Price at Filing: $21.72
Real-time Price: $23.25 info
Change: +$1.53 (+7%) info
Market Cap: $1.384B info
WWB
Nov 16, 2026, 5:22 PM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $30.04
Real-time Price: $23.25 info
Change: -$6.79 (-23%) info
Market Cap: $1.384B info
WWB
Nov 16, 2026, 4:01 PM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $30.04
Real-time Price: $23.25 info
Change: -$6.79 (-23%) info
Market Cap: $1.384B info
WWB
Nov 12, 2026, 6:19 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: N/A
Real-time Price: $23.25 info
Change: N/A info
Market Cap: $1.384B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets